Company Overview of Pasteur Institute
25-28 Rue Doctor Droux
Key Executives for Pasteur Institute
Vice President and Head of Applications
Compensation as of Fiscal Year 2014.
Pasteur Institute Key Developments
The Institut Carnot Curie Cancer Presents at BIO-Europe Spring 2015, Mar-10-2015 10:00 AM
Mar 6 15
The Institut Carnot Curie Cancer Presents at BIO-Europe Spring 2015, Mar-10-2015 10:00 AM. Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Moderna Therapeutics Enters into Research Collaboration with Institut Pasteur
Feb 5 15
Moderna Therapeutics has entered into a long-term strategic research collaboration with Institut Pasteur. The contract has been signed to discover and develop drugs and vaccines using its mRNA Therapeutics platform. It will be managed by its venture company, Valera, which is focused on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases. Under the deal, Valera will sponsor programmes of preclinical and clinical research at the Institut Pasteur, aimed at discovering and developing new approaches to combat known and emerging viral and bacterial diseases.
Myriad RBM Joins Institut Pasteur in the Global Fight against Tuberculosis
Jan 20 15
Myriad RBM announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis (TB) epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative (SATVI) clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture® system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis. Myriad RBM will supply the study with its revolutionary TruCulture collection systems. Once the blood samples are collected, Myriad RBM and the Institut Pasteur will seek to discover protein biomarkers important in regulating the immune system response using Myriad RBM's proprietary MAP (Multi-Analyte Profiling) platform.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries